Sentence: From August 2008 to May 2011 , consecutive chemo-naïve patients with stage IV non-squamous non-small cell lung cancer ( NSCLC ) received pemetrexed 500mg/m(2 ) , oxaliplatin 100mg/m(2 ) and bevacizumab 7.5mg/kg every 3 weeks for 6 cycles , in the outpatient setting .
Drug combination annotation:
[{'class': 'POS', 'spans': ['pemetrexed', 'oxaliplatin', 'bevacizumab'], 'is_context_needed': True}]